SelectScience InterviewsDrug Discovery & Development

Assessing efficacy and safety of CAR T-cell therapies

11 Sept 2024
Cameron Smith-Craig
Cameron Smith-Craig
Pharma and Applied Sciences Editor
Assessing efficacy and safety of CAR T-cell therapies

Dr. James Keck, Senior Director for Innovation and Product Development at The Jackson Laboratory, presents a novel PBMC humanized mouse model to assess efficacy and safety of CAR T-cell Therapy. He covers basic experimental design, toxicity and efficacy, cytokine induction, and more.

This video was filmed in partnership with The Jackson Laboratory.

About the company

The Jackson Laboratory logo

The Jackson Laboratory

The Jackson Laboratory is a global leader in preclinical studies and has been driving therapeutic development breakthroughs for over 90 years. With the most innovative preclinical platforms including humanized mice, and services such as dose ranging, toxicity, and efficacy studies, JAX empowers drug developers and researchers worldwide.

Other videos from The Jackson Laboratory

Links

Tags

Animal ModelsThe use of non-human animals in experiments or behavorial observations. The research is conducted inside universities, medical schools, pharmaceutical companies, farms, defence establishments, and commercial facilities that provide animal-testing services to industry. It includes pure research such as genetics, developmental biology, behavioral studies, as well as applied research such as pharmaceutical testing in pre-clinical, before human, studies. CAR-T cell therapy
Assessing efficacy and safety of CAR T-cell therapies